Pharma Marketing Yearbook (PMY) is a commemorative record of pharmaceutical marketing issues and highlights of the past year. It is published annually by Pharmaguy (aka, John Mack) in conjunction with Pharma Marketing News and Ph...

The shooting in Arizona was reprehensible and is a disgrace.  However part of the disgrace is that people who are obviously mentally ill are likely to go untreated as budget shortfalls force states to cut spending on everything from state medical co

Medication misuse can lead to hospitalizations and deaths. Those preventable events cost the healthcare system $100 billion to $300 billion annually, according to a 2009 report by the Pharmaceutical Research and Manufacturers of America.  Is it time

The Pharma Marketing Yearbook (PMY) is a commemorative record of pharmaceutical marketing issues and highlights of the past year.

Lessons learned.  While no one can argue that the environment in which the drug industry markets drugs has changed I believe that there is plenty to argue about "what have we learned?"   Specifically I am talking about the way DTC marketers do busi

Manhattan Research’s ePharma Consumer® study shows the ePharma Consumer population continues to grow, boosted in part by the increase in the number of older consumers using the Internet in recent years. In 2010, 112 million or 48% of U.S. adults w

Boniva continues to use Sally Field as a celebrity spokesperson for their product but as John Mack pointed out should any prescription drugs be paying celebrities to endorse their products ?  Well according to an Ace Metrix study the answer to that

Report: Boomers will shape m-health technology efforts Boomers view tech-enabled health products as a way to foster control and ongoing independence for themselves, especially in light of the rise in incidence in chronic disease with aging, and th

Hi Diabetes Online Community! I’m Laura Kolodjeski, the Community Manager for sanofi-aventis U.S. diabetes. Welcome to the new Discuss Diabetes™ blog. The purpose of Discuss Diabetes? To create a space where we can engage in two-way dialogue.  E

If you can find a path with no obstacles, it probably doesn't lead anywhere. ~ Frank A. Clark .  It's really good to see a pharma company finally embrace social media and break away from the pack.  Will the Sanofi-Aventis site be successful ?  At

GlaxoSmithKline took a $2.36 billion charge last summer to settle what it called “the substantial majority” of Avandia product liability lawsuits, as well as Paxil product liability cases and a Puerto Rico manufacturing case. But it has received

In the annals of fraudulent science, said Michael Fumento, no study did more damage than the one that linked autism to childhood vaccines. That 1998 study has since been disproved by more than 100 subsequent studies, and last week, the British Medica

At one point in time statins were thought to a super drug.  Why not give them to everyone including people who were at low risk for CV disease ?  Now comes a study from a British medical journal that says the opposite.  Then there are the people w

I can understand pharma's reluctance to jump into social media because of the risk in an environment where the FDA is in transformation.   What I can't really understand is why more healthcare marketers don't use social media to gather customer feed

Alfred Mann's $925 million bet on a fast-acting inhaled insulin program that hoped to succeed where Pfizer and Eli Lilly had already thrown in the towel--has run straight into another serious setback at the FDA. After a series of delays pushed the ag

Survey of U.S. Physicians Finds Pessimism on Future of Health Care A new survey of U.S. physicians finds they are decidedly pessimistic about the health-care overhaul law, with 65% saying it will contribute to a worsening of health-care quality ov

Last year I was hired to present social media basics to two physicians groups here in California.  One group had 5 physicians and is what is known as immediate care, no appointment needed, and the other was a group of 4 PCP family physicians. After